$PFE (+1.91%) thrown out with approx. -24%.
Reallocation to something more sensible.
If the 🔪 falls, we buy more via a savings plan.
Posts
141$PFE (+1.91%) thrown out with approx. -24%.
Reallocation to something more sensible.
If the 🔪 falls, we buy more via a savings plan.
Hello, I'm new to Getquin.
I'm interested in learning little by little about the world of finance.
I think a growth/dividend balance is interesting in a long-term strategy.
Today, I'm looking for alternatives in the healthcare sector in Europe or the USA, with cheap stocks with a growth/dividend balance.
Any recommendations?
Looking something similar than:
Thanks.
This is my actual portfolio.
🔹 EPS: $0.63 (Est. $0.48) 🟢
🔹 Revenue: $17.8B (Est. $17.28B) 🟢; UP +22% YoY
🔸 Pfizer anticipates $4.5B in cost savings by 2025.
FY25 Guidance:
🔹 EPS: $2.80-$3.00 (Est. $2.93) 🟡
🔹 Revenue: $61B-$64B (Est. $63B) 🟡
🔹 Adjusted SI&A Expenses: $13.3B-$14.3B
🔹 Adjusted R&D Expenses: $10.7B-$11.7B
🔹 Effective Tax Rate: ~15%
Segment Performance:
🔹 Biopharma Revenue: $17.41B (UP +23% YoY)
🔹 Pfizer CentreOne (PC1): $325M (DOWN -11% YoY)
🔹 Pfizer Ignite: $26M (UP +30% YoY)
Key Drug & Product Highlights:
🔹 Comirnaty (COVID-19 Vaccine): $3.4B (DOWN -38% YoY)
🔹 Paxlovid: $727M (UP +3.9B YoY, vs. -$3.1B prior Q4 due to one-time reversal)
🔹 Legacy Seagen Portfolio: $915M (Prev. $132M in Q4’23)
🔹 Vyndaqel Family: UP +60% YoY
🔹 Eliquis: UP +13% YoY
🔹 Xtandi: UP +24% YoY
🔹 Nurtec ODT/Vydura: UP +39% YoY
Declining Products:
🔹 Abrysvo: DOWN -62% YoY (Decline in U.S. vaccinations)
🔹 Xeljanz: DOWN -29% YoY (Due to label changes & exclusivity loss in Canada)
🔹 Oncology Biosimilars: DOWN -35% YoY (Supply constraints & price declines)
Operational Cost & Expense Metrics (Q4 2024):
🔹 Cost of Sales: $5.91B (Prev. $7.56B); DOWN -22% YoY
🔹 SI&A Expenses: $4.27B (Prev. $4.57B); DOWN -7% YoY
🔹 R&D Expenses: $3.04B (Prev. $2.82B); UP +8% YoY
🔹 Effective Tax Rate: 19.2%
Capital Allocation & Shareholder Returns:
🔹 Total R&D Investments: $10.8B
🔹 Dividends Paid: $9.5B ($1.68 per share)
🔹 No Share Repurchases in 2024
🔹 Remaining Share Buyback Authorization: $3.3B (No repurchases expected in 2025)
Strategic Developments & Pipeline Updates:
🔸 Braftovi Combo (Colorectal Cancer): Positive Phase 3 results, showing significant survival benefits.
🔸 Hympavzi (Hemophilia A treatment): Received European Commission approval.
🔸 Ibrance (Breast Cancer): Phase 3 data shows improved progression-free survival.
In the following post, I would like to discuss the new US tariffs and their potential economic consequences. The background and the potential impact on inflation and companies, as well as the winners and losers on the stock market, will be discussed.
Again, of course, the stocks mentioned do not constitute investment advice, but merely serve as examples of possible beneficiaries or losers of tightening trade restrictions. Historical developments are no guarantee of future returns.
__________
In this post:
__________
The topic of "tariffs" is currently not only very present in the media, but the term "tariffs" has also been discussed with a strong increase in the past earnings calls of companies in the S&P 500, as the following chart shows [1].
The chart shows that the discussion about tariffs has intensified in recent months and is having an ever greater impact on the outlook in companies' annual reports.
The data is presented as a three-month average and broken down into various sectors, including e.g. industry, healthcare, consumer goods, information technology, etc.
I am curious to see how the stock markets will behave in the coming week. In addition to the current reporting season, the topic of "tariffs" will certainly dominate.
After the tough tariffs announced after Trump took office were not immediately enforced and there was a "slight" sigh of relief, there could now be a new reaction on the markets, as there was on Friday evening. slightly was already slightly noticeable on Friday evening when the markets turned towards the evening.
A looming trade conflict could not only affect individual companies, but also further fuel inflation in the US:
💰 Influence on inflation
On January 31, Deutsche Bank published a forecast on the potential impact of tariffs on the inflation rate [2]:
The chart compares the current forecast with the forecast before the "Trump" era and takes into account various scenarios for the passing on of tariffs (pass-through) by Canada and Mexico.
Two scenarios are considered: one with a 50% pass-through of tariffs (additional increase shown in dark green) and one with a 75% pass-through (light green). It is clear that the inflation rate could rise sharply again this year and fall again by 2027.
🛃 New tariffs in force & further measures planned
As of today, February 1, 2025, the US government and Donald Trump have imposed new import tariffs on Mexico, Canada and China:
According to the White House spokesperson, these measures are, among other things, a response to the failure of these countries to stop the influx of fentanyl and illegal immigrants into the USA. [3]
But this is just the beginning:
From mid-February, the USA will also impose tariffs on strategic goods [4], including:
🚨 Trump relies on escalation - Canada announces retaliation
Yesterday, Canadian government representatives, including Foreign Minister Mélanie Joly, tried to prevent the tariffs in Washington, but to no avail.
Trump made it clear before his departure to Mar-a-Lago [5]:
"We have a 200 billion dollar trade deficit with Canada. Why should we subsidize Canada?"
The EU could also soon be targeted, as Trump hinted:
"Absolutely! The European Union has treated us so terribly!"
🔄 Canada's reaction:
Prime Minister Justin Trudeau announced that Canada will not back down and will respond with "swift and robust countermeasures".
The government is planning a three-stage retaliation strategy [5]:
However, this last step in particular would be a double-edged sword, as Canada is heavily dependent on energy cooperation with the USA.
Economic experts in the US are already warning of the consequences of a trade war [5]:
But Trump remains firm:
"Maybe there will be short-term disruption, but in the long run the tariffs will make us very rich and very strong."
🌎 Possible consequences for the global economy
(a) Rising prices in the USA
(b) Retaliation & new trade wars?
(c) Effects on the stock market
🏆 Winners & losers - which companies will benefit, which will suffer?
Possible beneficiaries of the tariffs
US manufacturers of steel, aluminum & copper
Domestic pharmaceutical and biotech companies
Energy companies with US production
Chip manufacturers with US production
😥 Companies that could suffer from the tariffs
Chip manufacturers with global supply chains
Car manufacturers with global suppliers
Companies with strong export business
US retailers with a high import share
🧠 Possible investment strategies
Favor defensive sectors:
Exploit long-term opportunities in "reshoring":
Conclusion: Will the trade conflict escalate further?
With the new tariffs, Trump is taking a confrontational stance and Canada, Mexico and China are preparing for retaliatory measures. If further tariffs on European goods follow, the situation could worsen.
❓Which stocks do you think could be most affected? Which beneficiaries do you see?
Thanks for reading! 🤝
__________
Sources:
[4]
[5] https://www.tagesschau.de/ausland/amerika/usa-trump-strafzoelle-100.html
Pizer ($PFE (+1.91%) ) shared breakthrough Phase 3 CREST trial results for sasanlimab, an anti-PD-1 monoclonal antibody, combined with BCG therapy for BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC).
🔑 Key Highlights:
✅ Primary Goal Achieved: Significant boost in event-free survival (EFS) vs. BCG alone.
🏆 First Advance in 30+ Years: Could be the first PD-1 inhibitor approved for this tough-to-treat cancer.
🌍 Global Impact: Targets ~100K new cases/year, with 40-50% facing recurrence.
🤝 Safety Check: Aligned with known safety profiles of PD-1 inhibitors and BCG.
Pfizer plans to submit these pivotal results for regulatory approval soon, aiming to redefine treatment options for patients with limited bladder-sparing choices.
💼 This progress strengthens Pfizer’s oncology pipeline and reinforces its position in innovative cancer care.
💬 Let's Chat !
What are your thoughts on Pfizer’s latest advancements in bladder cancer treatment? Could this mark a new era for non-muscle invasive bladder cancer therapies? Share your insights in the comments, like this post, and pass it along to your network ! 👍🏻
Big win for Astellas ($ALPMY ) and Pfizer ( $PFE (+1.91%) )!
China’s NMPA just approved Padcev™ (enfortumab vedotin) + Keytruda® as the first non-platinum option in 40 years for locally advanced/metastatic urothelial cancer (la/mUC).
🔑 Key Stats from Phase 3 EV-302 Trial:
Overall Survival: 31.5 months (vs. 16.1 with chemo) 🚀
Progression-Free Survival: 12.5 months (vs. 6.3 with chemo) 📉
With over 92K bladder cancer cases in China last year, this approval disrupts decades of reliance on platinum-based chemo and opens a massive market opportunity.
This approval underscores a pivotal shift in treatment options for bladder cancer, providing new opportunities for patients and adding momentum to Astellas and Pfizer’s oncology portfolios.
Pfizer ( $PFE (+1.91%) ) has just secured FDA approval for Braftovi® in combination with cetuximab (Erbitux®) and mFOLFOX6 chemotherapy to treat patients with metastatic colorectal cancer (mCRC) who have a BRAF V600E mutation. This marks a major milestone in the fight against one of the toughest forms of cancer, offering new hope for patients with limited treatment options.
🔬 Why It Matters:
The FDA's decision was based on impressive results from Pfizer's Phase 3 BREAKWATER trial, showing a significant increase in the response rate (61% vs. 40%) compared to standard care.
This approval is part of the FDA’s Project FrontRunner, fast-tracking innovative cancer treatments.
Braftovi’s approval opens the door for continued expansion of Pfizer’s cancer portfolio.
🧐 Investor Insight:
With this approval, Pfizer strengthens its oncology pipeline, signaling potential growth in cancer drug sales. Investors should keep an eye on this development as the company moves to address one of the most challenging cancers in the market.
📊 What’s Next?
The safety and efficacy of Braftovi will be further assessed, with results from ongoing trials expected soon. Investors, take note—Pfizer’s oncology growth story may be accelerating!
Let’s discuss: Could Pfizer’s continued innovation in cancer treatments make it a top pick in the biotech sector while being currently undervalued? Drop your thoughts below! 💬👇
In Part 1 I described my start as an investor from 2010 to 2016. Despite loss-making investments and bad decisions (buying AT&T instead of Amazon), I was able to achieve a portfolio value of €35,000. These experiences were to lay the first foundation stone for my future successful investment strategy (https://app.getquin.com/de/activity/PElWrODsmV)
In part 2 I talk about further setbacks in 2017 and 2018 and how the purchase of MasterCard shares marked the turning point in my investment career. Despite initial losses and professional dissatisfaction, I realized that my original strategy wasn't working and discovered the "dividend growth" for me. With a new professional position and a solid salary, I was finally able to really hit the ground running in 2019 (https://app.getquin.com/de/activity/LUkWiLtZKX)
In part 3 it will now be about the years 2019 to 2021 will be discussed. In these 3 years, my portfolio has increased fivefold. From €40,000, it went up to €199,000 in the meantime. But not everything was positive here either. During this time, I also made the two worst trades of my investment career. In addition to Wirecard, there were two other equity investments that resulted in losses of over 80%.
The year 2019 & the first share savings plans:
The year 2019 started with a portfolio balance of ~€40,000 and after my MasterCard purchase in December 2018, my major portfolio reorganization was to continue directly at the beginning of 2019. So in the first four months with Tencent $700 (+2.88%)
Intel $INTC (-4.07%)
Salesforce $CRM (-2.41%)
Alphabet $GOOG (-2.32%) and Meta $META (-1.11%) (then still Facebook), five more tech stocks were added to my portfolio. In return I have BHP Billiton $BHP (-0.19%)
Macy's $M (-3.7%)
and Hugo Boss $BOSS (+0.31%) sold.
Later in the year, the shares of Mercedes $MBG (-1.31%)
and AT&T $T (+2.01%) were also removed from the portfolio.
In addition to further acquisitions such as Pepsi $PEP (+3.26%)
Nextera Energy $NEE (+2.37%)
or Xylem $XYL (-1.46%) I also recognized the benefits of share savings plans in 2019 and started to set up a pure "savings plan custody account". At that time, this was still done via comdirect or Consorsbank and each savings plan execution cost a fee of 0.75%.
Another sale in 2019 was the Gamestop-share $GME (-1.75%) . Bought in 2016 to have something to do with gaming in the portfolio, but not taking into account that stationary sales are becoming less and less relevant. In the end, the share price fell by 85% - unfortunately, this was long before the memestock hype emerged.
My portfolio rose to ~€67,000 in 2019 and achieved a return of 23%. However, this was still well below the MSCI World and the S&P 500.
The year 2020 - Corona, Wirecard bankruptcy & 100k before 30 in the portfolio
2020 - a year that few of us will probably forget. While everything was still going reasonably smoothly in January and February 2020, chaos was set to break out from mid-February/March.
The first few weeks of 2020 had given rise to hopes of a very positive development in my portfolio. From the beginning of January to mid-February, my portfolio rose by almost €10,000 to €77,000.
Panic then slowly set in from mid-February. I still remember exactly how trading on the US stock markets was repeatedly suspended for short periods and daily losses of 10% were normal. At 0 o'clock sharp, I looked at the US futures and in seconds the futures went down by -5%. A cap for the futures, the futures loss must not be higher and you knew the next morning it would end badly for the DAX.
But when there is blood in the streets, you can make very good deals! So in March 2020 I bought the Allianz
$ALV (-0.14%) for €118. This gives me a personal dividend yield of almost 12% based on the current dividend of €13.80. Unfortunately, I only bought for €1,000 in total.
Also Starbucks
$SBUX (-0.91%) I was able to buy for less than €50.
The stock market crash continued until the Fed made short work of it and ended the crash single-handedly. The crash was ended with interest rate cuts and massive money printing and once again the saying "Never bet against the FED" proved to be true.
The stock markets then went through the roof and within a very short space of time were already back to a positive level compared to the end of 2019. Every share that somehow falls under the term "stay at home" was suddenly the hot tip on the stock market. Whether the Peloton $PTON (-5.46%)
or Teladoc $TDOC (-8.8%) everything went through the roof.
I let myself get carried away and did about 10 "Stay at Home" hype stocks into a growth savings plan portfolio. Of these, at the end of 2024 with Sea $SE (-2.53%) and MercadoLibre $MELI (-4.31%) only two shares remained. It goes without saying that most of them left the portfolio at a loss.
But 2020 was also the Wirecard year $WDI (-33.51%) BaFin's ban on short selling, a year-long audit by EY, political backing and massive investments by German fund managers from DWS, UnionInvest and Deka vs. a journalist from the Financial Times.
Wirecard's claims that the journalist was in cahoots with short sellers and the backing from various institutions were unfortunately too credible for me.
When Wirecard faced the press and announced that EUR 2 billion could no longer be found, things went downhill and it became clear to everyone that the company was heading for insolvency. Before trading was suspended, I was able to sell my shares at a 50% loss and got off lightly.
Later in the year, I was able to conclude an extremely favorable leasing offer and sell my private car. The proceeds went straight into my securities account and I broke the €100,000 barrier in November 2020.
My portfolio then ended the year with a value of ~€120,000. At +5%, my performance was pretty much in line with the MSCI World.
The year 2021 - HYPE! Wall Street bets, crypto and almost 200k in the portfolio
The year 2021 was characterized above all by hypes. Cryptocurrencies, memestocks and memecoins were in the headlines everywhere. Gamestop, Dogecoin, SPACs and NFTs everyone had to have.
Traditional shares became almost boring.
One of the reasons was certainly the checks that the US government issued to its citizens. It was still Corona, many were locked down and suddenly people started gambling on the stock market.
The hype can be illustrated very well using the example of NFTs. In 2021, NFTs worth $17 billion were traded, in 2023 it was only 80 million - a decline of 97%. According to one study, ~95% of all NFTs are now completely worthless.
The madness in one example: Procter & Gamble launched a Charmin toilet paper NFT. This was sold for over $4,000. All proceeds were donated, but a symbol of the madness of 2021.
From a portfolio perspective, 2021 was great! In the end, there was a +32% return and a portfolio value of over €190,000, which at times in November 2021 was €199,000.
My top performers were NVIDIA
$NVDA (-3.63%) with over 100% price gains and Pfizer $PFE (+1.91%)
, which was driven by the vaccine hype and at €50 was twice as high as in 2024.
My worst performer was another 80% loss with TAL Education $TAL (+0.36%) . An education company from China. Unfortunately, this was the first time I was able to experience the political arbitrariness in countries like China. Overnight, it was decided that education/tutoring could only be run as a non-profit. Of course, this was almost a death sentence for the company and the share price plummeted by 80%.
Asset development & return:
After the years 2013 to 2018 were forgettable in terms of returns, the years 2019 to 2021 finally delivered:
Year
Deposit value
Yield
2019 67.000€ +19%
2020 121.000€ +5%
2021 193.000€ +34%
Vermögensentwicklung 2019-2021:
Vermögensentwicklung 2013-2021:
Outlook:
Looking back on the hype year 2021, it is almost obvious that 2022 had to be clearly negative.
After the party, however, came the hangover in the form of inflation and the war in Ukraine. Sharply rising interest rates and global economic concerns did the rest.
In the next part, I would therefore like to look at the years 2022 & 2023. I will then combine 2024 with my review of the year in the last part.
PFIZER $PFE (+1.91%) GUIDES FY25 BASICALLY IN-LINE, FOCUSES ON COST SAVINGS
- FY25 Revenue: $61B-$64B (vs $62.9B expected)
- Adj EPS: $2.80-$3.00 (vs $2.90 expected)
- Pfizer sees $500M additional savings in 2025, building on its $4B cost realignment.
- Manufacturing optimization on track for cost improvements in H2'25.
-IRA-related changes to Part D expected to impact revenue by ~$1B YoY.
Pfizer's Ibrance Shows Promise in Treating Metastatic Breast Cancer
Pfizer ($PFE (+1.91%)) announced positive Phase 3 trial results for its drug Ibrance in combination with standard therapies for HR+, HER2+ metastatic breast cancer.
The PATINA study revealed that patients receiving Ibrance alongside anti-HER2 and endocrine therapies experienced a median progression-free survival (PFS) of 44.3 months, compared to 29.1 months with standard therapies alone.
While overall survival data is still pending, these findings were presented at the San Antonio Breast Cancer Symposium. Ibrance is already approved for treating HR+, HER2- advanced or metastatic breast cancer in combination with other therapies.
Top creators this week